EVOTEC SE - ADR

EVO12 Dec 2024
Healthcare
$4.66
+0.00 (+0.21%)
Lowest Today
$4.58
Highest Today
$4.68
Today’s Open
$4.66
Prev. Close
$4.67
52 Week High
$12
52 Week Low
$2.85
To Invest in EVOTEC SE - ADR

EVOTEC SE - ADR

Healthcare
EVO12 Dec 2024
+0.00 (+0.21%)
1M
3M
6M
1Y
5Y
Low
$4.58
Day’s Range
High
$4.68
4.58
52 Week Low
$2.85
52-Week Range
52 Week High
$12
2.85
1 Day
-
1 Week
+1.85%
1 month return
-4.31%
3 month return
+36.25%
6 month return
-1.89%
1 Year return
-52.49%
3 Years return
-80.08%
5 Years return
-
10 Years return
-
Institutional Holdings
Novo A/S
4.18
Mubadala Investment Company PJSC
1.29
Wellington Management Company LLP
0.74
LVIP Wellington SMID Cap Value Std
0.14
VALIC Company I Mid Cap Value
0.12
EQ/Mid Cap Value Managed Volatil IB
0.09
Empower Mid Cap Value/Wellington SP
0.07

Market Status

Fundamentals
Market Cap
1695.94 mln
PB Ratio
1.6
PE Ratio
0
Enterprise Value
1745.17 mln
Total Assets
2299.05 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Organisation
EVOTEC SE - ADR
Employees
5007
Industry
Drug Manufacturers - Specialty & Generic
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step